Rizatriptan Benzoate Tablet
Product Images NDC 71335-2979

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Rizatriptan Benzoate (NDC 71335-2979). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label (Lbl713352979)

Label (Lbl713352979)
This text contains information about a medication called Rizatriptan Benzoate Tablets, USP. Each tablet contains 7.265 mg of Rizatriptan Benzoate, which is equivalent to 5 mg of Rizatriptan. It provides directions for usual adult dosage, storage conditions, and precautions such as keeping the medication out of the reach of children. The package insert QR code is mentioned for further details. The medication is to be dispensed in a tight, light-resistant container. It also provides the NDC (National Drug Code) number and the details of the manufacturer, Bryant Ranch Prepack, Inc., and Alkem Laboratories Ltd.*
FDA Label Image

Rizatriptan-fig-1 (Rizatriptan Fig 1)

Rizatriptan-fig-1 (Rizatriptan Fig 1)
This text provides a graphical representation of the probability of response to different dosages of Rizatriptan Benzoate compared to a placebo over a period of 10 hours post-dose. The percentages indicate the likelihood of response at different time points after taking either the placebo or varying doses of Rizatriptan Benzoate.*
FDA Label Image

Rizatriptan-fig-2 (Rizatriptan Fig 2)

Rizatriptan-fig-2 (Rizatriptan Fig 2)
This is information related to the estimated probability of needing additional medication or rescue intervention after taking either Rizatriptan Benzoate 5 mg or Rizatriptan Benzoate 10 mg at various hours post-dose, as compared to a placebo. The data indicates the percentage of users that may require remedication or rescue intervention within the provided time frame.*
FDA Label Image

Rizatriptan-fig-5 (Rizatriptan Fig 5)

FDA Label Image

Rizatriptan-structure (Rizatriptan Structure)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.